Protara Therapeutics, Inc. — Director's Dealing 2018

Feb 9, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2018-02-08

Reporting Person: NOYES TIMOTHY P (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-08	Stock Option (Right to Buy)	$2.15	A	500000	Acquired	2028-02-07	Common Stock, $0.001 par value (500000)	Direct

Footnotes

F1: The options were granted on February 8, 2018 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.